SCHEMBL1476488

SCHEMBL1476488

CN(C(=O)OCc1cc(-c2ccco2)on1)c1ccncc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.54
RAB9A P51151 6/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
POLB P06746 5/20 0.46
MAPT P10636 4/20 0.46
KMT2A Q03164 3/20 0.45
GAA P10253 2/20 0.45
LMNA P02545 3/20 0.44
THRB P10828 2/20 0.44
TSHR P16473 1/20 0.42
HPGD P15428 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 2/20 0.41
TP53 P04637 1/20 0.41
EPHX2 P34913 2/20 0.41
HTT P42858 2/20 0.40
ROCK2 O75116 1/20 0.40
MEN1 O00255 2/20 0.39
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1476492 0.76 NPC1 (0.56) NPC1RAB9AL3MBTL1POLBMAPT
SCHEMBL1476803 0.72 RAB9A (0.58) NPC1RAB9AL3MBTL1POLBMAPT
SCHEMBL14948947 0.71 RAB9A (0.55) NPC1RAB9AL3MBTL1POLBMAPT
SCHEMBL1475256 0.71 RAB9A (0.59) NPC1RAB9AL3MBTL1POLBMAPT
SCHEMBL1474743 0.71 HPGD (0.64) NPC1RAB9AL3MBTL1POLBMAPT
SCHEMBL14470267 0.69 RAB9A (0.56) NPC1RAB9AL3MBTL1POLBMAPT
SCHEMBL1474697 0.69 RAB9A (0.56) NPC1RAB9AL3MBTL1POLBMAPT
SCHEMBL14946441 0.68 RAB9A (0.52) NPC1RAB9AL3MBTL1POLBMAPT
SCHEMBL1475114 0.68 EPHX2 (0.54) NPC1RAB9APOLBMAPTKMT2A
SCHEMBL1474547 0.67 NOTUM (0.59) NPC1RAB9AL3MBTL1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 NPC1 2242/4885RAB9A 2013/4885L3MBTL1 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.